About this trial
The goal of this prospective, single-center and observational study is to develop and validate an optimization algorithm for single-lead ECG conduction intervals via the wearable ECG patches combined with synchronized heart sound data, and evaluate its agreement with the clinical gold standard (12-lead ECG) in adult patients. The main question: Does the optimized algorithm, based on ECG patches and synchronous heart sound recordings, improve the detection accuracy of PR interval, QRS duration, and QT interval compared with standard 12-lead ECG? It aims to answer: Participants (age ≥18 years, BMI \<35 kg/m², stable sinus rhythm with at least one abnormal conduction interval) will first undergo a 2-minute session of simultaneous ECG patches and digital stethoscope recordings, followed by standard 12-lead ECG, and then the repeated ECG patches and 2-minute heart sound recording session. Data will be used for algorithm training and validation. The primary endpoint is the accuracy of the optimized PR interval, QRS duration, and QT interval detection via the Vivalink ECG patches compared with the 12-lead ECG.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years;
Body mass index < 35 kg/m²;
with stable sinus rhythm;
PR interval, QRS duration, or QT interval were stable and at least one was outside the normal range;
Disqualifiers
Physical disabilities that prevent safe and thorough testing;
Open wounds on the chest or skin is allergy to patches;
Post-implantation of temporary or permanent cardiac pacemaker, ICD, CRT or CRTD, post-replacement of artificial heart valve, with large amounts of pericardial effusion, pericardial tamponade, pleural friction rub, pneumothorax, large amounts of pleural effusion, etc., which may affect data collection;
Patients with severe comorbidities or unstable condition, which may interfere with data collection during the study period;
Trial population
Adult patients with stable sinus rhythm, at least one stable and abnormal conduction interval (PR, QRS, or QT)
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
PR interval
QRS duration
QT interval
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Vivalink
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator